BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Catalyst Brief//FDA catalyst calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Catalyst Brief — FDA catalyst calendar
REFRESH-INTERVAL;VALUE=DURATION:PT6H
X-PUBLISHED-TTL:PT6H
BEGIN:VEVENT
UID:event-84@catalystbrief.girapphe.com
DTSTAMP:20261117T061556Z
LAST-MODIFIED:20261117T061556Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:Readout: AstraZeneca — Durvalumab [Jan 2027]
DESCRIPTION:Phase 3 primary completion: A Global Study to Assess the Effect
 s of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Co
 ncurrent Chemoradiation in Patients With Stage III Unresectable Non-Small 
 Cell Lung Cancer.\nSource: https://clinicaltrials.gov/study/NCT05221840\nh
 ttps://catalystbrief.girapphe.com/e/84?lang=en\nNot investment advice. Dat
 es may change.
URL:https://catalystbrief.girapphe.com/e/84?lang=en
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
